DGAP-News: MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
Retrieved on:
Wednesday, October 20, 2021
Constellation, Safety, Disease, Autoantibody, BLA, Urine, Communication, Degenerative disease, Clinical trial, MM, Inflammation, Immune system, CD38, Incidence, Blood, Judgement, FSE, Interstitial lung disease, Food, U.S. Securities and Exchange Commission, Lymphoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Senior, Annual report, Autoimmune disease, Physician, Indoleamine 2,3-dioxygenase, China, Industry, Antibody, B cell, Chronic kidney disease, LLC, Lenalidomide, Risk, Patient, MD, Cancer, Immunoglobulin A, NASDAQ, Psoriasis, Janssen Pharmaceuticals, Kidney bean, Kidney, Asia, Multiple myeloma, Glomerulosclerosis, Pharmaceutical industry, IgAN, MorphoSys, IGAN, MORPHOSYS
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN).
Key Points:
- MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN).
- "Dosing of the first IgAN patient is an exciting milestone for MorphoSys, physicians and patients alike as we are rapidly broadening our development program for felzartamab."
- Felzartamab (MOR202) is an investigational therapeutic human monoclonal antibody derived from MorphoSys' HuCAL(R) antibody library and directed against CD38.
- By targeting CD38, felzartamab has the potential to deplete the CD38 positive plasma cells, which may ultimately improve the patient's kidney functions.